|
One in four deaths in the United States each year are due to heart disease, according to the Centers for Disease Control and Prevention. It's the leading killer of both men and women, but the disease's genetic complexity makes it difficult to treat. | |
|
|
Cardiovascular disease patients have lower levels of an important family of protective molecules in their blood in the morning, which could be increasing their risk of blood clots and heart attacks at those times, according to early research led by Queen Mary University of London. | |
|
|
New research has shown how vitamin D may help protect heart tissue and prevent heart failure after a heart attack, potentially offering a low-cost addition to existing treatments for heart failure. | |
|
|
Doctors caring for severe stroke patients need to take account of their psychological needs and help prepare families for the possibility that they may not recover, a study suggests. | |
|
|
Cleveland Clinic researchers found that implementing a four-step protocol for the most severe type of heart attack not only improved outcomes and reduced mortality in both men and women, but eliminated or reduced the gender disparities in care and outcomes typically seen in this type of event. | |
|
|
New findings, presented today at the American College of Cardiology, provide long-term information about survival, stroke rates and durability of a novel centrifugal-flow pump compared with a commercial axial flow pump for heart-failure patients. | |
|
|
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in patients with acute coronary syndrome who were randomly assigned to receive dual antiplatelet therapy for either six months or at least 12 months after receiving a drug-eluting stent. | |
|
|
Heart failure is more common, develops earlier and results in higher rates of illness and death in African Americans than in whites. | |
|
|
Researchers in Hamilton have discovered that a blood-thinning drug, dabigatran, significantly reduces the risk of death, heart attack, stroke, and other heart or blood-vessel complications in patients who have a heart injury following major, non-cardiac surgery. | |
|
|
Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily activity levels, severity of symptoms or quality of life in patients with a type of heart failure for which no effective treatment options currently exist, according to research presented at the American College of Cardiology's 67th Annual Scientific Session. | |
|
|
This article describes the structure of the heart, position and role of the heart valves, and how damage can lead to valvular heart disease. | |
|
|
When Marc Hammer went to the emergency room feeling fatigued and dizzy, he had no idea his life was actually at risk. "I'm an avid cyclist and walk five to 15 miles a day," said Hammer, "so you can imagine my shock when I found out I was facing a heart issue. It came out of the blue." | |
|
|
Protein pathways that are closely linked to changes in both triglyceride and hemoglobin A1c levels in diabetic patients have been identified in new research by the Intermountain Medical Center Heart Institute in Salt Lake City. | |
|
|
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting. | |
|
|
Wearing a lightweight vest equipped with a cardioverter defibrillator that detects abnormal heart rhythms in addition to taking recommended medications is associated with a reduction in the likelihood of dying during the first 90 days following a heart attack in people whose heart function was also impaired, according to a study presented at the American College of Cardiology's 67th Annual Scientific Session. | |
|
|
Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events by 15 percent compared with placebo, in a study presented at the American College of Cardiology's 67th Annual Scientific Session. | |
No hay comentarios:
Publicar un comentario